Allergic Conjunctivitis - Pipeline Review, H1 2020
Allergic Conjunctivitis - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H1 2020, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.
Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 2, 8 and 1 respectively.
Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H1 2020, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.
Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 2, 8 and 1 respectively.
Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Allergic Conjunctivitis - Overview
Allergic Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Allergic Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Allergic Conjunctivitis - Companies Involved in Therapeutics Development
Ajanta Pharma Ltd
Aldeyra Therapeutics Inc
Allakos Inc
Allergan Plc
Clevexel Pharma SAS
Dhp Korea Ltd
Eleusis Ltd
iCo Therapeutics Inc
JW Pharmaceutical Corp
Marinomed Biotech AG
Ocular Therapeutix Inc
OKYO Pharma Ltd
Portola Pharmaceuticals Inc
RAPT Therapeutics Inc
Re-Pharm Ltd
Sylentis SAU
Allergic Conjunctivitis - Drug Profiles
(alcaftadine + ketorolac tromethamine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGN-229666 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AK-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bertilimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DHPNP-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELE-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketotifen SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OKYO-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRT-2761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reproxalap - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPT-193 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Histamine 4 Receptor for Age Related Macular Degeneration and Allergic Conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYL-116011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tacrolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergic Conjunctivitis - Dormant Projects
Allergic Conjunctivitis - Discontinued Products
Allergic Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Feb 24, 2020: Aldeyra Therapeutics to provide update on late-stage clinical development pipeline at 2020 Research & Development Day
Jan 22, 2020: Aldeyra Therapeutics begins enrolment in allergic conjunctivitis study
Oct 31, 2019: Aldeyra Therapeutics releases expanded results from allergen chamber trial and announces plans to initiate the phase 3 INVIGORATE trial in patients with Allergic Conjunctivitis
Oct 30, 2019: Aldeyra Therapeutics to host conference call and webcast to release expanded results from allergen chamber trial and announce design of Phase 3 INVIGORATE trial in patients with allergic conjunctivitis
Oct 23, 2019: Eleusis presents new research on the anti-inflammatory potential of serotonin 2A receptor agonists at the 2019 International Society for Research on Psychedelics
Sep 26, 2019: Aldeyra Therapeutics to present phase 3 ALLEVIATE trial results in allergic conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting
Sep 24, 2019: Ocular Therapeutix announces first patient dosed in phase 3 clinical trial of DEXTENZA for the treatment of Allergic Conjunctivitis
May 07, 2019: Allakos announces positive Results with AK002 in patients with Severe Allergic Conjunctivitis
Apr 24, 2019: Ocular Therapeutix to present new data on DEXTENZA at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
Mar 27, 2019: Aldeyra’s ALLEVIATE trial of reproxalap eyedrops meets endpoints
Mar 25, 2019: Aldeyra Therapeutics schedules webcast and conference call to announce top-line results from the phase 3 ALLEVIATE trial in Allergic Conjunctivitis
Dec 20, 2018: Aldeyra Therapeutics announces last patient dosed in the ALLEVIATE phase 3 clinical trial
Nov 28, 2018: Viennese Biotech company Marinomed demonstrates the benefits of its patented Marinosolv Technology of Tacrosolv
May 07, 2018: Sylentis announces new data on the treatment of allergic conjunctivitis
Apr 24, 2018: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Allergic Conjunctivitis - Overview
Allergic Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Allergic Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Allergic Conjunctivitis - Companies Involved in Therapeutics Development
Ajanta Pharma Ltd
Aldeyra Therapeutics Inc
Allakos Inc
Allergan Plc
Clevexel Pharma SAS
Dhp Korea Ltd
Eleusis Ltd
iCo Therapeutics Inc
JW Pharmaceutical Corp
Marinomed Biotech AG
Ocular Therapeutix Inc
OKYO Pharma Ltd
Portola Pharmaceuticals Inc
RAPT Therapeutics Inc
Re-Pharm Ltd
Sylentis SAU
Allergic Conjunctivitis - Drug Profiles
(alcaftadine + ketorolac tromethamine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGN-229666 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AK-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bertilimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DHPNP-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELE-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketotifen SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OKYO-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRT-2761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reproxalap - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPT-193 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Histamine 4 Receptor for Age Related Macular Degeneration and Allergic Conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYL-116011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tacrolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergic Conjunctivitis - Dormant Projects
Allergic Conjunctivitis - Discontinued Products
Allergic Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Feb 24, 2020: Aldeyra Therapeutics to provide update on late-stage clinical development pipeline at 2020 Research & Development Day
Jan 22, 2020: Aldeyra Therapeutics begins enrolment in allergic conjunctivitis study
Oct 31, 2019: Aldeyra Therapeutics releases expanded results from allergen chamber trial and announces plans to initiate the phase 3 INVIGORATE trial in patients with Allergic Conjunctivitis
Oct 30, 2019: Aldeyra Therapeutics to host conference call and webcast to release expanded results from allergen chamber trial and announce design of Phase 3 INVIGORATE trial in patients with allergic conjunctivitis
Oct 23, 2019: Eleusis presents new research on the anti-inflammatory potential of serotonin 2A receptor agonists at the 2019 International Society for Research on Psychedelics
Sep 26, 2019: Aldeyra Therapeutics to present phase 3 ALLEVIATE trial results in allergic conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting
Sep 24, 2019: Ocular Therapeutix announces first patient dosed in phase 3 clinical trial of DEXTENZA for the treatment of Allergic Conjunctivitis
May 07, 2019: Allakos announces positive Results with AK002 in patients with Severe Allergic Conjunctivitis
Apr 24, 2019: Ocular Therapeutix to present new data on DEXTENZA at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
Mar 27, 2019: Aldeyra’s ALLEVIATE trial of reproxalap eyedrops meets endpoints
Mar 25, 2019: Aldeyra Therapeutics schedules webcast and conference call to announce top-line results from the phase 3 ALLEVIATE trial in Allergic Conjunctivitis
Dec 20, 2018: Aldeyra Therapeutics announces last patient dosed in the ALLEVIATE phase 3 clinical trial
Nov 28, 2018: Viennese Biotech company Marinomed demonstrates the benefits of its patented Marinosolv Technology of Tacrosolv
May 07, 2018: Sylentis announces new data on the treatment of allergic conjunctivitis
Apr 24, 2018: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Allergic Conjunctivitis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Allergic Conjunctivitis - Pipeline by Ajanta Pharma Ltd, H1 2020
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H1 2020
Allergic Conjunctivitis - Pipeline by Allakos Inc, H1 2020
Allergic Conjunctivitis - Pipeline by Allergan Plc, H1 2020
Allergic Conjunctivitis - Pipeline by Clevexel Pharma SAS, H1 2020
Allergic Conjunctivitis - Pipeline by Dhp Korea Ltd, H1 2020
Allergic Conjunctivitis - Pipeline by Eleusis Ltd, H1 2020
Allergic Conjunctivitis - Pipeline by iCo Therapeutics Inc, H1 2020
Allergic Conjunctivitis - Pipeline by JW Pharmaceutical Corp, H1 2020
Allergic Conjunctivitis - Pipeline by Marinomed Biotech AG, H1 2020
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, H1 2020
Allergic Conjunctivitis - Pipeline by OKYO Pharma Ltd, H1 2020
Allergic Conjunctivitis - Pipeline by Portola Pharmaceuticals Inc, H1 2020
Allergic Conjunctivitis - Pipeline by RAPT Therapeutics Inc, H1 2020
Allergic Conjunctivitis - Pipeline by Re-Pharm Ltd, H1 2020
Allergic Conjunctivitis - Pipeline by Sylentis SAU, H1 2020
Allergic Conjunctivitis - Dormant Projects, H1 2020
Allergic Conjunctivitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Allergic Conjunctivitis - Discontinued Products, H1 2020
Number of Products under Development for Allergic Conjunctivitis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Allergic Conjunctivitis - Pipeline by Ajanta Pharma Ltd, H1 2020
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H1 2020
Allergic Conjunctivitis - Pipeline by Allakos Inc, H1 2020
Allergic Conjunctivitis - Pipeline by Allergan Plc, H1 2020
Allergic Conjunctivitis - Pipeline by Clevexel Pharma SAS, H1 2020
Allergic Conjunctivitis - Pipeline by Dhp Korea Ltd, H1 2020
Allergic Conjunctivitis - Pipeline by Eleusis Ltd, H1 2020
Allergic Conjunctivitis - Pipeline by iCo Therapeutics Inc, H1 2020
Allergic Conjunctivitis - Pipeline by JW Pharmaceutical Corp, H1 2020
Allergic Conjunctivitis - Pipeline by Marinomed Biotech AG, H1 2020
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, H1 2020
Allergic Conjunctivitis - Pipeline by OKYO Pharma Ltd, H1 2020
Allergic Conjunctivitis - Pipeline by Portola Pharmaceuticals Inc, H1 2020
Allergic Conjunctivitis - Pipeline by RAPT Therapeutics Inc, H1 2020
Allergic Conjunctivitis - Pipeline by Re-Pharm Ltd, H1 2020
Allergic Conjunctivitis - Pipeline by Sylentis SAU, H1 2020
Allergic Conjunctivitis - Dormant Projects, H1 2020
Allergic Conjunctivitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Allergic Conjunctivitis - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Allergic Conjunctivitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Ajanta Pharma Ltd
Aldeyra Therapeutics Inc
Allakos Inc
Allergan Plc
Clevexel Pharma SAS
Dhp Korea Ltd
Eleusis Ltd
iCo Therapeutics Inc
JW Pharmaceutical Corp
Marinomed Biotech AG
Ocular Therapeutix Inc
OKYO Pharma Ltd
Portola Pharmaceuticals Inc
RAPT Therapeutics Inc
Re-Pharm Ltd
Sylentis SAU
Number of Products under Development for Allergic Conjunctivitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Ajanta Pharma Ltd
Aldeyra Therapeutics Inc
Allakos Inc
Allergan Plc
Clevexel Pharma SAS
Dhp Korea Ltd
Eleusis Ltd
iCo Therapeutics Inc
JW Pharmaceutical Corp
Marinomed Biotech AG
Ocular Therapeutix Inc
OKYO Pharma Ltd
Portola Pharmaceuticals Inc
RAPT Therapeutics Inc
Re-Pharm Ltd
Sylentis SAU
